ObjectivesThis study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil.BackgroundThere is no cure for PAH, despite effective treatments, and outcomes remain suboptimal. The addition of inhaled treprostinil, a long-acting prostacyclin analog, might be a safe and effective treatment addition to other PAH-specific oral therapies.MethodsTwo hundred thirty-five PAH patients with New York Heart Association (NYHA) functional class III (98%) or IV symptoms and a 6-min walk distance (6MWD) of 200 to 450 m while treated with bosentan (70%) or sildenafil were randomized to inhaled treprostinil (up to 54 μg) or inhaled placebo 4 times daily. Th...
BACKGROUND: Inhaled treprostinil was recently developed for the treatment of pulmonary arterial hype...
Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patien...
STUDY OBJECTIVES: To assess the efficacy and safety of continuous subcutaneous infusion of treprosti...
OBJECTIVES: This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arteria...
ObjectivesThis study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial ...
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hyperten...
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hyperten...
Background: Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hyper...
ObjectivesThis study sought to investigate the effects of inhaled treprostinil on pulmonary hemodyna...
Introduction: Pulmonary arterial hypertension is an increasingly recognized heterogeneous disease wi...
Oral treprostinil may be an option for low- and intermediate-risk patients with pulmonary arterial h...
Oral treprostinil has recently been shown to delay disease progression in patients with pulmonary ar...
Treprostinil diolamine is the first oral prostacyclin approved for the treatment of pulmonary arteri...
Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease process with a high morbidi...
Steven C Pugliese,1 Todd M Bull1,2 1Division of Pulmonary Sciences and Critical Care Medicine, Depar...
BACKGROUND: Inhaled treprostinil was recently developed for the treatment of pulmonary arterial hype...
Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patien...
STUDY OBJECTIVES: To assess the efficacy and safety of continuous subcutaneous infusion of treprosti...
OBJECTIVES: This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arteria...
ObjectivesThis study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial ...
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hyperten...
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hyperten...
Background: Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hyper...
ObjectivesThis study sought to investigate the effects of inhaled treprostinil on pulmonary hemodyna...
Introduction: Pulmonary arterial hypertension is an increasingly recognized heterogeneous disease wi...
Oral treprostinil may be an option for low- and intermediate-risk patients with pulmonary arterial h...
Oral treprostinil has recently been shown to delay disease progression in patients with pulmonary ar...
Treprostinil diolamine is the first oral prostacyclin approved for the treatment of pulmonary arteri...
Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease process with a high morbidi...
Steven C Pugliese,1 Todd M Bull1,2 1Division of Pulmonary Sciences and Critical Care Medicine, Depar...
BACKGROUND: Inhaled treprostinil was recently developed for the treatment of pulmonary arterial hype...
Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patien...
STUDY OBJECTIVES: To assess the efficacy and safety of continuous subcutaneous infusion of treprosti...